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ABSTRACT
Introduction Zika virus (ZIKV) infection in pregnancy 
has been associated with microcephaly and severe 
neurological damage to the fetus. Our aim is to document 
the risks of adverse pregnancy and birth outcomes and the 
prevalence of laboratory markers of congenital infection 
in deliveries to women experiencing ZIKV infection during 
pregnancy, using data from European Commission- funded 
prospective cohort studies in 20 centres in 11 countries 
across Latin America and the Caribbean.
Methods and analysis We will carry out a centre- by- 
centre analysis of the risks of adverse pregnancy and birth 
outcomes, comparing women with confirmed and suspected 
ZIKV infection in pregnancy to those with no evidence of 
infection in pregnancy. We will document the proportion of 
deliveries in which laboratory markers of congenital infection 
were present. Finally, we will investigate the associations 
of trimester of maternal infection in pregnancy, presence or 
absence of maternal symptoms of acute ZIKV infection and 
previous flavivirus infections with adverse outcomes and with 
markers of congenital infection. Centre- specific estimates 
will be pooled using a two- stage approach.
Ethics and dissemination Ethical approval was obtained 
at each centre. Findings will be presented at international 
conferences and published in peer- reviewed open access 
journals and discussed with local public health officials 
and representatives of the national Ministries of Health, 
Pan American Health Organization and WHO involved with 
ZIKV prevention and control activities.
INTRODUCTION
Following the emergence of Zika virus 
(ZIKV) in Asia and the Pacific in 20131 and 
the subsequent introduction to Brazil,2 clus-
ters of neonates with severe neurological 
Strengths and limitations of this study
 ► This will be a pooled analysis of data from three in-
ternational consortia conducting prospective cohort 
studies of outcomes following Zika virus (ZIKV) in-
fection in pregnancy in 20 centres in 11 countries.
 ► Standardised definitions of outcomes will provide 
clarity about the absolute risks of adverse outcomes, 
which have not been reported consistently in pro-
spective studies so far.
 ► These studies include a control group of women with 
no evidence of ZIKV infection in pregnancy, allowing 
improved estimation of the proportion of adverse 
events attributable to ZIKV in pregnancy.
 ► Inferences will be limited by: difficulties in distin-
guishing between women who did and who did not 
experience a ZIKV infection in pregnancy, due to the 
high frequency of mild and asymptomatic infections 
and the low sensitivity and specificity of diagnos-
tic tools; low diagnostic sensitivity of markers of 
congenital infection; and outcome data that are not 
missing at random.
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complications and microcephaly were observed across 
Latin America. Following recent experiences with the 
H1N1 influenza pandemic and Ebola outbreak in Western 
Africa, the need for coordinated international research 
on ZIKV was quickly recognised. In January 2016, before 
WHO declared a Public Health Emergency of Interna-
tional Concern,3 the European Commission (EC) issued 
a funding call to set up a network in Latin America and 
the Caribbean with the aim of implementing and coordi-
nating urgently required research, while simultaneously 
contributing to research capacity and preparedness for 
other emerging infectious diseases. Three consortia were 
funded: ZIKAlliance (https:// zikalliance. tghn. org/),4 5 
ZikaPLAN6 (https:// zikaplan. tghn. org/) and ZIKAction 
(http:// zikaction. org/). All are multidisciplinary inter-
national collaborations with active investigations in 
epidemiology, virology, immunology, diagnostics, math-
ematical modelling, social science and animal studies. 
Each consortium includes its own prospective cohort 
study of ZIKV in pregnancy and a shared work package 
that aims to ensure the harmonisation of protocols and 
data sets in order to facilitate a pooled analysis of cohort 
data. The primary aim of the pooled analysis is to investi-
gate the incidence of adverse outcomes of ZIKV infection 
in pregnancy, including ‘congenital infection, micro-
cephaly, Zika congenital syndrome and other sequelae of 
ZIKV infection’.
The aim of this paper is to present a protocol for 
this pooled analysis. Data have been or are still being 
collected in multiple sites in 20 regional coordinating 
centres spread over 11 countries and regions across 
Latin America and the Caribbean. There are 15 ZIKAlli-
ance centres: Sao Paulo, Rio de Janeiro, Recife and Belo 
Horizonte (Brazil); Valencia (Venezuela); Bucaramanga 
(Colombia); Guayaquil (Ecuador); Lima (Peru); Jalisco, 
Nayarit, Veracruz, Yucatan (Mexico); Santa Cruz de la 
Sierra (Bolivia); Havana (Cuba); Guadeloupe (French 
Territory of the Americas); 3 ZikaPLAN centres: Goiânia, 
Rio de Janeiro, Recife (Brazil) and 2 ZIKAction centres: 
Kingston (Jamaica) and Port- au- Prince (Haiti). Recruit-
ment to ZIKAlliance began May 2017, December 2015 for 
ZikaPLAN, and September 2017 for ZIKAction. Over 700 
women with confirmed infection had been recruited by 
April 2020.
Several studies of ZIKV in pregnancy have recently 
been published. In registry- based studies,7–9 fetuses and 
newborns of women with confirmed infection in preg-
nancy have been reported to have ‘potentially Zika- related’ 
adverse outcomes at rates of up to 15%, with higher risk 
of Zika- associated adverse outcomes in the first trimester. 
Registry- based studies are likely to overestimate the risk of 
severe clinical manifestations and underestimate the risk 
of more mild clinical presentations because they recruit 
both prospectively ascertained ZIKV- infected pregnant 
women and women whose infection was recognised 
retrospectively following the birth of an infant with 
congenital abnormalities. Prospective studies of congen-
ital infection have variously reported 25% ‘severe’ and 
21% ‘mild to moderate’ outcomes in French Guiana,10 
and 27% adverse outcomes in Brazil.11 The specificity of 
these outcome definitions for ZIKV in pregnancy is not 
known as these studies did not include a control group of 
women with no ZIKV infection in pregnancy. In another 
Brazilian study, the risk of adverse outcomes was reported 
to be 46% in births to women with NAAT (Nucleic Acid 
Amplification Test)- confirmed ZIKV infection in preg-
nancy compared with 11.5% in NAAT- negative women.12 
In a large prospective study based in the French Terri-
tories of the Americas, among infants born to women 
with NAAT- confirmed ZIKV infection, 7.0% presented 
with neurologic or ocular birth defects and 3.1% met the 
study’s criteria for Congenital Zika Syndrome (CZS),13 
which is characterised by several unique features.14 An 
important limitation in the comparison of the results of 
these different studies is the lack of a standard definition 
of CZS and of the clinical and diagnostic procedures used 
to evaluate these children, leading to possible misclassifi-
cation of the outcomes studied.
The vertical transmission rate is the probability of 
congenital infection in births to women with infection in 
pregnancy. The rates reported so far, 26%11 and 35%,10 
are based on laboratory markers of congenital infection 
such as NAAT or IgM in the fetus or newborn. However, 
a prospective cohort retrospectively reconstructed from 
a register study estimated the vertical transmission rate 
to be only 9%.15 Comparison of these rates is difficult as 
different markers and different biological samples were 
used. In addition, although these tests (NAAT and IgM) 
are analytically sensitive and specific they have poor 
diagnostic sensitivity as markers of congenital infection. 
These markers were absent from serum in a high propor-
tion of CZS cases16 16 17 and in newborns with other poten-
tially ZIKV- related adverse outcomes born to women 
with confirmed ZIKV during pregnancy.10 11 Clearance 
of virus from amniotic fluid and fetal blood has been 
reported in cases of CZS, even when ZIKV is found in 
brain tissue postmortem.18 19 It, therefore, appears that 
fetal infection may occur, causing profound damage, 
but clearing before delivery and leaving no discernable 
immunological trace in serum. Consequently, in this 
study, we will document the prevalence of markers of 
congenital infection using uniform criteria, recognising 
that this is an underestimate of the true vertical trans-
mission rate.
Regarding effect modifiers, a number of studies have 
reported a higher incidence of congenital abnormalities 
following maternal infections in the first trimester.7 10 11 14 
Maternal symptoms during acute ZIKV infection do not 
appear to be a risk factor for adverse outcomes.20 There 
is evidence of antibody dependent enhancement of ZIKV 
by dengue virus (DENV) antibody in animal models,21 but 
it is unclear whether previous DENV infection or expo-
sure to other flaviviruses has a protective, risk- enhancing 
or null effect, in maternal or congenital infection in 
humans.22 It also remains to be established whether a 
previous ZIKV infection confers protective immunity. 
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Little is currently known about risk factors for transpla-
cental transmission of ZIKV.
The analysis plan described here complements the 
recently published protocol of the ZIKV Individual 
Participant Data (IPD) Consortium,23 which will eventu-
ally include data from the three EC consortia as well as 
data from many other sources. Although the objectives of 
the protocols are similar, different methods are proposed 
in relation to design of included studies, definition of 
congenital infection, and approach to imperfect diag-
nosis of maternal infection.
In light of the unexplained heterogeneity in reported 
rates of adverse outcomes, and the variation in preva-
lence of markers of congenital infection, a pooled anal-
ysis of data from 20 centres following similar protocols 
with harmonised definitions of clinical and laboratory 
outcomes will provide important new information on 
outcomes of ZIKV in pregnancy.
OBJECTIVES OF THE JOINT ANALYSIS
1. To estimate the risk of adverse outcomes in the fetus, 
newborn, and child following maternal ZIKV infection 
in pregnancy, compared with outcomes in controls 
with no evidence of maternal infection in pregnancy 
(MIP).
2. To estimate the prevalence of markers of congenital 
infection among fetuses and liveborn infants following 
maternal ZIKV infection during pregnancy.
3. To assess the associations between trimester of mater-
nal infection, presence or absence of maternal symp-
toms, and previous flavivirus infections with adverse 
outcomes and markers of congenital infection.
METHODS
Participants
Pregnant women were eligible only if their infection 
status during pregnancy (infected or not infected) was 
ascertained prior to the detection of adverse outcomes, 
or was not influenced by fetal examination or outcome 
on delivery. This definition is compatible with retrospec-
tive testing of previously collected maternal samples, after 
delivery. Although the unit of recruitment is the mother, 
the unit of analysis is the fetus, newborn and infant; 
multiple births are sufficiently rare to be treated as inde-
pendent observations.24
Study design
Consenting women were screened in pregnancy for 
markers of ZIKV infection. Those in whom MIP was 
suspected were followed with enhanced investigations. In 
ZIKAction and ZIKAlliance, all deliveries to these women, 
including fetal losses, stillbirths and newborns were 
examined clinically and tested for markers of congenital 
infection. This testing was not routinely performed in 
ZikaPLAN. In all three cohorts, newborns were prospec-
tively followed to identify any adverse outcomes that may 
develop later. In all three consortia, a sample of newborns 
delivered to women with no evidence of infection in preg-
nancy served as an unexposed control group.
There were some differences between the protocols 
adopted by the three consortia in terms of how women 
were recruited into the study, and the choice and sched-
uling of tests and investigations (online supplemental 
table S1). In ZIKAction and ZIKAlliance, women were 
recruited regardless of symptoms during pregnancy, 
although report of symptoms was recorded. In ZikaPLAN, 
only women with rash, a common sign of ZIKV infec-
tion, were recruited. Statistical analyses will therefore be 
stratified by whether the mother reported symptoms in 
pregnancy.
When the studies were designed, there was little infor-
mation on the risk of adverse outcomes of ZIKV in preg-
nancy, on vertical transmission rates, nor on what infection 
rates among pregnant women might be expected. Formal 
sample size calculations were not undertaken.
Patient and public involvement statement
There was no patient or public involvement in this study.
Target parameters and terminology of vertical transmission 
studies
Six categories of joint congenital infection status and 
maternal infection status (A–F) are defined in table 1, 
which illustrates the logic of an idealised prospective 
study. The usual target parameters are the vertical 
transmission rate, which is the probability of congen-
ital infection following MIP, (A+B) / (A+B+C+D); and 
the rate of adverse outcomes in those with congen-
ital infection, A/(A+B). The definitions of ‘adverse 
outcomes’, congenital infection and MIP will be 
determined by a Joint Diagnostics Group and a Joint 
Endpoint Review Group, after the data have been 
assembled. Estimates of these parameters are stan-
dard in the classic studies of vertical transmission of 
HIV,25 26 toxoplasmosis27–29 and cytomegalovirus.30 In 
studies of less specific outcomes, the event rate C/
(C+D) in fetuses and newborns of women with MIP 
but in whom no congenital infection occurred (paedi-
atric control group 1 in table 1) forms a comparison 
group31 32 representing the adverse event rate that is 
due to MIP in the absence of congenital infection. 
The present analysis plan is modelled closely on 
these earlier studies, but includes adaptations to take 
account of the difficulties in diagnosing maternal and 
congenital ZIKV infection.
For example, because cases of congenital infection 
cannot be reliably identified by diagnostic tests, we can only 
estimate the prevalence of laboratory markers of vertical 
infection (ie, NAAT or IgM) (Objective 2). Similarly, 
the ‘overall’ (unconditional) adverse event rate is taken 
as the primary outcome for objective 1; this includes all 
births to women with MIP, (A+C)/(A+B+C+D) (table 1). 
All three consortia included a further control group of 
births to unexposed women, those with no infection in 
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pregnancy (Maternal Control Group in table 1). The 
adverse event rates in this group, E/(E+F), represents a 
baseline for comparison with the overall event rates in 
exposed women.33
Although estimates of the vertical transmission rate 
are compromised, it may still be of interest to compare 
adverse outcome rates in the MIP with congenital infec-
tion group (ie, A/(A+B)), the MIP without congenital 
infection group (ie, C/(C+D)) and the No MIP group 
(ie, E/(E+F)), as this may provide insight into whether 
adverse fetal outcomes are associated with MIP in the 
absence of demonstrable fetal infection.
In addition to the challenges associated with the labo-
ratory definition of congenital infection, it is also diffi-
cult to discriminate between pregnancies with MIP and 
with No MIP as required in analyses based on table 1. A 
positive NAAT result or seroconversion during pregnancy 
are sufficient to confirm MIP. However, even if tested per 
protocol, MIP may be missed due to the narrow window 
of detection of NAAT tests, perhaps as low as 14 days.34 
Tests of recent infection, including IgM, IgG3 or avidity 
assays, may reflect infection during pregnancy, but may 
also be the result of infection prior to pregnancy,35 and 
immunological cross- reactivity to DENV antibody may 
need to be ruled out.36 These tests, therefore, indicate 
suspected but not confirmed MIP. An IgG negative 
response in the woman or newborn at or tests, perhaps as 
low as 14 days.34 An IgG negative response in the woman 
or newborn at or shortly after delivery can be taken as 
suggestive of No MIP, although the dynamics of ZIKV IgG 
are not well documented. While a negative IgG is likely 
to be uncommon in some sites, as some women will have 
experienced a ZIKV infection prior to pregnancy, it lowers 
the probability that a ZIKV infection would have occurred 
in pregnancy. Taking all this together, MIP status will be 
characterised as ‘Confirmed’, “Suspected, ‘No Evidence 
of MIP’ (ie, all NAAT and IgM tests negative), and ‘No 
MIP’ (ie, all NAAT and IgM tests negative and IgG nega-
tive at or shortly after delivery). To maintain the principle 
of prospective ascertainment, confirmation of congenital 
infection will have no impact on the mother’s assigned 
infection status.
Definitions of variables
To support the pooled analyses, a Joint Diagnostics Group 
consisting of immunologists and virologists and a Joint 
Endpoint Review Group consisting of paediatricians with 
experience of congenital ZIKV will be convened to agree 
on standardised case definitions. The names and qualifica-
tions of members of both groups will be published at the 
time of the joint data analysis, together with the rationale 
and process for their recruitment. Online supplemental 
table S2 provides some provisional definitions for: MIP 
(Confirmed, Suspected, No Evidence of MIP, No MIP), 
laboratory markers of congenital infection (present or 
absent), signs and symptoms compatible with CZS, other 
potentially Zika- related outcomes (OPZRO) and trimester 
of MIP. The Joint Diagnostics Group will also have respon-
sibility for definitions of covariates, such as previous flavi-
virus infection. Definitions of both diagnostic categories 
and clinical endpoints will be based on the best infor-
mation available at the time of analysis, and will, to the 
greatest extent possible, be harmonised across consortia 
and across centres within consortia. As the expert groups 
will be assembled from representatives of each consor-
tium, they will already have examined the data prior to a 
joint analysis, so that blinding will not be possible; however, 
they will devise diagnostic and clinical criteria that can be 
applied objectively across the three consortia.
An essential aspect of the definitions for MIP status 
used in the statistical analyses below is that they must be 
based exclusively on the prospective diagnostic testing. 
For example, although CZS and/or laboratory evidence 
of congenital infection in the newborn provides compel-
ling evidence of MIP, this would not affect the MIP 
status as ascertained prospectively. Thus, we expect to 
observe some newborns with CZS and/or with laboratory 
markers of congenital infection delivered to women with 
Suspected MIP, or even those categorised as having no 
evidence of MIP.
Table 1 Design of an idealised prospective vertical transmission study
Maternal infection status
MIP No MIP
Congenital Infection Status congenital infection Adverse outcomes A 0
No adverse outcomes B 0
No congenital infection Adverse outcomes C E
No adverse outcomes D F
The vertical transmission rate is estimated by (A+B)/ (A+B+C+D). The rate of adverse outcomes conditional on congenital infection is A/(A+B). This 
can be compared with the rate of adverse outcomes in newborns with no congenital infection, C/(C+D), who form a control group (Paediatric control 
group) to account for potential confounders associated with maternal infection. An overall, non- conditional estimate of the adverse eventrate is 
(A+C)/(A+B+C+D). Follow- up of births to women with no MIP creates a second control group (maternal control group), in which the rate of adverse 
outcomes, E/(E+F), can be compared with the rate in births with no congenital infection to womenwith MIP. Estimated effects of MIP based on 
the maternal control group are vulnerable to confounding by factors associated with MIP. Some cells are set to zero as there can be no congenital 
infection without MIP.
MIP, maternal infection in pregnancy.
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STATISTICAL ANALYSIS
Analysis of data from individual centres
Descriptive tables
We will produce descriptive tables providing a break-
down of the numbers in each centre with confirmed MIP, 
suspected MIP, no Evidence of MIP and no MIP, and the 
type of evidence on which this is based (eg, NAAT, serocon-
version, tests of recent infection) (online supplemental 
table S3). The similar online supplemental table S4 will 
document numbers with signs or symptoms compatible 
with CZS and with markers of congenital infection, and 
the type of evidence on which this is based, for example 
NAAT, IgM or clinical markers (CZS).
Objective 1: adverse outcomes
Prospectively ascertained MIP status will be tabulated 
against overall (ie, unconditional on congenital infection 
status) adverse outcomes (table 2). Various risks can be 
estimated within each MIP category, including: the risk 
of signs and symptoms compatible with CZS, the risk of 
OPZRO, the risk of both combined, of individual signs 
and symptoms or of signs and symptoms grouped in clin-
ically (eg, ophthalmological defects) or embryologically 
meaningful ways. Outcomes may be binary (eg, micro-
cephaly) or continuous (eg, head circumference) or 
multicategory (CZS- related outcomes, OPZRO, asymp-
tomatic). As well as congenital anomalies, rates of stan-
dard outcomes, in the absence of congenital anomalies, 
will be documented, including: fetal loss, stillbirth, low 
birth weight, intrauterine growth retardation (IUGR) 
and premature delivery.
The rate of adverse outcomes in the no MIP group 
represents the study- specific background rate of adverse 
outcomes (ie, in the absence of MIP, cntrol group 2), to 
be compared with rates in women with confirmed MIP. 
Absolute risks will be estimated as well as risk ratios and 
risk differences.
Parallel sets of estimates will be calculated in the 
suspected MIP and no evidence of MIP groups, as partic-
ular adverse events indicate lack of diagnostic specificity 
and sensitivity in the testing protocol during pregnancy 
and are therefore informative regarding the effective-
ness of the maternal testing protocol in each centre; for 
example, microcephaly in the No Evidence of MIP group 
would indicate a lack of sensitivity. These sets of estimates 
may be pooled, respectively, with adverse outcome risks in 
Confirmed MIP and No MIP groups in sensitivity analyses.
Objective 2: laboratory and clinical markers of vertical transmission
Estimates of the prevalence of markers of congenital 
infection will be produced in all centres with available 
data for each MIP group except the no MIP group, as the 
definition of No MIP is not compatible with laboratory 
markers of congenital infection. For this purpose, the 
numerator will be the number with markers of congenital 
infection, and the denominator will be the sum of the 
numbers with and without markers of congenital infec-
tion. Separate estimates will be obtained for: laboratory 
markers, clinical markers (namely CZS), and combined 
laboratory and clinical markers (table 3). Rates in the no 
evidence of MIP group are of interest as they carry infor-
mation about the diagnostic accuracy of the maternal 
testing protocol.
Objective 3: effect of covariates
Separate estimates of the prevalence of adverse preg-
nancy outcomes, and the probability of laboratory and 
clinical markers of congenital infection, will be produced 
for each trimester of maternal infection, and by presence 
or absence of maternal symptoms.
Analyses of adverse event frequencies and of markers of 
congenital infection can be extended to include multiple 
covariates, using logistic regression. These might include 
potential effect modifiers, such as previous arbovirus 
infection or coinfection, or confounding factors such as 
socioeconomic indicators likely to be associated with both 
arbovirus exposure and adverse outcomes. However, at 
the time of writing it is not known whether sufficient data 
will be available for regression analyses.
Secondary objectives
ZIKV infection in pregnancy could lead to adverse preg-
nancy and birth outcomes either following a congen-
ital infection (cell A in table 1) or in the absence of 
congenital infection (equally in cells A and C). Although 
absence of markers of congenital infection does not 
Table 2 Scheme for a generic analysis of risks of adverse outcomes by prospectively ascertained MIP status
Centre
MIP
Confirmed Suspected No Evidence of MIP No MIP
Symptom 1         
Symptom 2         
Symptom 3         
:         
No symptoms         
Total         
Presence or absence of fetal and neonatal signs or symptoms (eg, microcephaly, brain calcifications, arthrogryposis) and other potentially Zika- 
related outcomes (eg, fetal loss) in the different MIP groups will be compared.
MIP, maternal infection in pregnancy.
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rule out congenital infection, we might still expect to 
observe more adverse outcomes in fetuses and newborns 
with laboratory markers of congenital infection if those 
outcomes are caused by congenital infection. By contrast, 
adverse outcomes that are the result of MIP in the absence 
of congenital infection (Cell E in table 1) should occur 
equally with or without laboratory markers of congenital 
infection. Based on literature on other infections in preg-
nancy, including DENV,37 adverse outcomes associated 
with MIP in the absence of congenital infection poten-
tially include: fetal loss, stillbirth, prematurity, IUGR 
and low birth weight for gestational age.38 The analysis 
would be based on a tabulation of presence or absence of 
neonatal symptoms, or sets of symptoms (online supple-
mental table S5), and would be stratified by trimester of 
maternal infection, as this is likely to be associated with 
the presence of markers of congenital infection and with 
adverse outcomes.
Missing covariates
All analyses will be conducted on a ‘complete case’ basis, 
in the first instance. Methods for handling missing covari-
ates, such as imputation,39 will be considered after the 
extent and patterns of missing data have been explored.
Combining data across centres
The above analyses will generate a series of centre- 
specific estimates of proportions, relative risks comparing 
MIP and No MIP groups, risk- differences and means of 
continuous variables, stratified by trimester and maternal 
clinical presentation. If logistic regression is used to 
examine effect modifiers and confounders, further esti-
mates of interaction terms or adjusted estimates can also 
be produced.
All these estimates can be combined across centres 
using fixed or random effects models in a ‘two- stage’ meta- 
analysis. Bayesian Markov chain Monte Carlo methods 
will be used as this will facilitate the use of exact binomial 
and multinomial likelihoods, which have a better perfor-
mance with low and zero cells counts. Vague priors will be 
employed. Centre- specific random effect estimates will be 
sampled from beta distributions for binomial outcomes 
data, Dirichlet distributions for multinomial data and 
normal distributions for continuous data. We will report 
ranges, between- centre SD, mean effects and predictive 
effects with 95% credible intervals for each estimate.
In combining estimates from different centres, we will 
take account of the fact that in ZikaPLAN only women 
with rash were recruited, so that women with no ZIKV 
infection may have experienced other exanthematic 
infections,12 including arbovirus infections such as 
dengue and chikungunya, which may themselves be asso-
ciated with adverse outcomes.40 41
Depending on the results of two- stage analyses, and the 
completeness of covariate data, an individual patient data 
one- stage meta- analyses will be considered for each objec-
tive, as a secondary or sensitivity analysis, with centre as an 
additional fixed ‘intercept’ term.
Sensitivity analyses
Definitions of MIP status, ZIKV-related outcomes and laboratory 
markers of congenital infection
We will report differences in adverse event rates between 
Confirmed MIP and Suspected MIP, and between No 
Evidence of MIP and No MIP. If the differences are small, 
we will produce results pooling these categories as a sensi-
tivity analysis.
Further, the No Evidence of MIP category can be subdi-
vided into women who were tested per protocol and 
those who may have been tested less completely. The 
impact of compliance with protocols will be explored, 
as it is expected to impact on the proportion of women 
with MIP who are classified as ‘no evidence of MIP’ and, 
hence, on the probability of observing adverse outcomes 
in this group. Similarly, we will conduct sensitivity anal-
yses around the definitions of Confirmed and Suspected 
MIP on advice from the Joint Diagnostics Group.
Alternative sets of estimates will be generated using 
alternative criteria for CZS- related outcomes and OPZRO, 
that are more, or less, specific for ZIKV in pregnancy. 
Similarly, we will explore the impact of varying the labora-
tory criteria for congenital infection on the advice of the 
Joint Diagnostics Group.
Independent ascertainment of outcomes
A critical requirement of all these analyses is that the 
ascertainment of markers of congenital infection status 
and clinical outcomes in the fetuses and newborns, and 
Table 3 Scheme for generic analysis of markers of congenital infection by prospectively ascertained MIP status
Centre
MIP
Confirmed Suspected No Evidence of MIP No MIP
Both laboratory and clinical markers of congenital infection         
Only laboratory markers of congenital infection         
Only clinical markers of congenital infection         
No markers of congenital infection         
Not tested         
Total         
Markers of congenital infection may include laboratory markers, clinical markers, such as microcephaly or both combined.
MIP, maternal infection in pregnancy.
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developing infant are all independent of each other, and 
also independent of MIP status. For example, ideally the 
same laboratory testing for congenital infection is carried 
out regardless of whether the pregnancy outcome is a 
fetal loss, termination of pregnancy, stillbirth, a case of 
CZS, or an apparently healthy asymptomatic infant.
These assumptions are difficult, and in certain respects 
(eg, first trimester fetal loss and terminations) not 
possible, to fully implement in practice. To address these 
inevitable limitations in the analysis, which are expected 
to impact more on objective 2 than on objective 1, we 
will carry out exploratory analyses aimed at detecting 
potential deviations from protocol. For example, the 
distribution of trimester of MIP should not be associated 
with prospectively ascertained MIP status. Guided by the 
results, we will carry out sensitivity analyses that make a 
range of assumptions about the distribution of missing 
data, especially data on markers of congenital infection. 
A series of scenarios will be examined to assess robustness 
of results to inherent and/or unplanned deviations from 
the ideal protocols required for unbiased estimation of 
the target parameters.
DISCUSSION
Risks of CZS and other adverse birth outcomes of ZIKV 
infection in pregnancy can only be assessed through 
studies that recruit women whose infection status is 
prospectively ascertained, or, if retrospective, ascertain-
ment is independent of outcomes. However, reported 
risks of adverse outcomes even from prospective studies 
have been highly variable,10–13 as have vertical transmis-
sion rates based on laboratory markers of congenital ZIKV 
infection.10 11 15 An important role for joint analyses of 
multiple studies is to explore whether this heterogeneity 
in outcomes can be explained by individual or study- level 
covariates. To do this, it is essential that incidental sources 
of variation, such as those arising from differences in 
outcome reporting or diagnostic testing, are controlled 
or eliminated as much as possible. One of the most diffi-
cult sources of variation between consortia, and between 
sites within consortia, lies in diagnosis of maternal infec-
tion. Our approach is to have an Expert Diagnostics 
Group produce a harmonised classification of confirmed 
MIP, suspected MIP, no Evidence of MIP and no MIP, 
and to compute a range of estimates of the relative effect 
of maternal infection on outcomes, grouping these in 
different ways. An analysis based on the confirmed MIP 
and no MIP groups alone would be expected to generate 
the largest estimates of relative effect, because both poor 
sensitivity and poor specificity will tend to bias effect esti-
mates towards the null.
An alternative proposal23 in relation to maternal infec-
tion status is to treat test sensitivity and specificity as 
study- level covariates in a meta- regression, but the risk of 
false positive diagnosis depends more on the incidence 
of ZIKV and cross- reacting antibodies to other arbovirus 
infections such as dengue than on test specificity. The 
ZIKV IPD Consortium protocol differs in two other ways. 
First it proposes to include surveillance studies, which 
may result in overestimating the risk of adverse outcomes 
due to retrospective ascertainment of infected women 
following adverse newborn outcomes.7 9 Second, congen-
ital infection is to be defined by clinical and radiological 
criteria alone.
Other statistical methods may have been developed by 
the time the data becomes available for these analyses. 
Whatever form of analysis is adopted, a standardised 
pooled analysis from three large consortia comprising 
20 centres will provide valuable information about these 
parameters, which will assist in framing a public health 
response and advice to women who might be exposed 
in future. It may also throw light on pathological mech-
anisms leading to adverse outcomes, which could help 
in the development of therapeutic or prophylactic 
interventions.
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